Malignant Melanoma
Conditions
Brief summary
This study, with 20 patients participating, will examine the safety and tolerability for the ipilimumab/UV1 combination in patients with unresectable or metastatic malignant melanoma.
Detailed description
This is a phase I/IIa, national, open label, single arm, interventional study examining safety and tolerability for the ipilimumab/UV1 combination in patients with unresectable or metastatic malignant melanoma. Patients that have signed the informed consent form will be asked to take part in the study. All patients will receive ipilimumab together with the UV1 vaccine and rranulocyte-macrophage colony-stimulating factor (GM-CSF). Ipilimumab will be given every 3rd week for a total of 4 doses. The UV1 vaccine and GM-CSF will be given before and between treatments of ipilimumab. The maximum number of UV1/GM-CSF will be 10 doses. Immunoresponders maybe followed up every third months for 5 years after the first UV1 treatment. Follow-up is onging.
Interventions
DRUGIpilimumab
BIOLOGICALUV1 vaccine
BIOLOGICALGM-CSF
Sponsors
Oslo University Hospital
Ultimovacs ASA
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Histologically or cytologically confirmed diagnosis of unresectable or metastatic malignant melanoma, including cutaneous, ocular, mucosal and unknown primary tumour. 2. Unresectable Stage III or Stage IV melanoma (AJCC 2010) 3. Prior adjuvant melanoma therapy is permitted; any number of previous treatments for melanoma is permitted. 4. ECOG performance status of 0 or 1 (see Error! Reference source not found.). 5. Men and women ≥ 18 years of age 6. Adequate hematologic, renal and hepatic function, specifically: 1. WBC ≥ 2500/μL 2. Absolute neutrophil count (ANC) ≥ 1000/uL 3. Platelets ≥ 75 x 103/μL 4. Haemoglobin ≥ 9 g/dL 5. Creatinine ≤ 2.5 x ULN 6. AST/ALT ≤ 3 x ULN for patients without liver metastasis; ≤ 5 x ULN for patients with liver metastasis 7. Total bilirubin ≤ 3 x ULN, (except patients with Gilbert's Syndrome, who must have a total bilirubin less than 3.0 mg/dL) 7. Women of childbearing potential and men must be using an acceptable method as described in the protocol to prevent pregnancy. 8. Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented according to ICH GCP, and national/local regulations.
Exclusion criteria
1. History of or current active autoimmune diseases, including but not limited to inflammatory bowel diseases, rheumatoid arthritis, autoimmune thyroiditis, autoimmune hepatitis, systemic sclerosis (scleroderma and variants), systemic lupus erythematosus, autoimmune vasculitis, autoimmune neuropathies (e.g. Guillain-Barre syndrome). Patients with vitiligo are not excluded. 2. MRI detected active brain metastasis witch require other therapies such as surgery and/or radiation therapy. Patients already treated for their brain metastasis, surgery or radiation therapy, and have had stable disease for more than two month and NOT requiring steroids may however be included in this study. 3. Uncontrolled infectious diseases - requires negative tests for clinically suspected human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV). 4. History of or current immunodeficiency disease, splenectomy or splenic irradiation 5. Prior allogeneic stem cell transplantation 6. Pregnancy 7. Women who are breastfeeding 8. Any underlying medical or psychiatric condition, which in the opinion of the Investigator, will make the administration of study drug hazardous or obscure the interpretation of Adverse Events, such as a condition associated with frequent diarrhoea 9. History of allergic reaction to parenteral administered recombinant protein product 10. History of another malignancy that in the opinion of the investigator may compromise the outcome of the study 11. Any reason why, in the opinion of the investigator, the patient should not participate. 12. Known serious reactions or hypersensitivity to any components of the UV1 vaccine or similar peptide based vaccines 13. Known hypersensitivity to GM-CSF 14. Known hypersensitivity to any of the excipients of the investigational products 15. Concomitant use of antithrombotic agents with the exception of platelet inhibitors.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety and tolerability profile. Frequency/ severity of adverse and serious adverse events. Biochemistry and hematology results, vital signs and ECOG | Up to 53 weeks | Frequency and severity of adverse events and serious adverse events. Biochemistry and hematology results, vital signs and ECOG performance status will be assessed. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Immunological response. Number of T-cell responses including time to T-cell response, level of response and duration of response. | Up to 53 weeks | Number of T-cell responses including time to T-cell response, level of response and duration of response. |
| Treatment response. Tumour response evaluated by CT scan every 12th week. | Up to 48 weeks | Tumour response evaluated by CT scan every 12th week. |
| Health Related Quality of Life (HRQL) | Up to 53 weeks | HRQL measured by use of patient questionnaire EORTC QLQ-C30 |
Other
| Measure | Time frame | Description |
|---|---|---|
| Explore potential biomarkers for efficacy and safety of the ipilimumab/UV1 combination | Up to 48 weeks | Exploratory biomarker analysis. |
Countries
Norway
Outcome results
None listed